Net Pals Net Pals
Arama Sonuçları
Tüm Sonuçları Gör
  • Katıl
    Giriş yapın
    Başvur
    Site içinde arama yapın
    Night Mode

Site içinde arama yapın

Yeni insanlarla keşfedin, yeni bağlantılar oluşturmak ve yeni arkadaşlar edinmek

  • Web sayfası bildirimcisi
  • EXPLORE
  • Sayfalar
  • Gruplar
  • Events
  • Reels
  • Blogs
  • Market
  • Offers
  • Jobs
  • Yazı
  • Blogs
  • Kullanıcılar
  • Sayfalar
  • Gruplar
  • Events
  • anjushinde13 bir ses eklendi Health
    2026-07-22 10:16:31 - Translate -
    Common Drugs Use In Ophthalmology Market Competitive Landscape Overview
    The Common Drugs Use In Ophthalmology Market continues to expand as ophthalmologists, optometrists, and eye care specialists increasingly rely on established pharmacological agents to manage the growing spectrum of ocular diseases affecting vision and quality of life. With common ophthalmic drugs including anti-VEGF agents, prostaglandin analogs, corticosteroids, antibiotics, anti-allergy...
    0 Yorumlar 0 hisse senetleri 371 Views 0 önizleme
    Please log in to like, share and comment!
  • mahir007 bir ses eklendi Other
    2026-11-18 10:01:12 - Translate -
    Aflibercept Market Size, Share, Trends & Forecast 2033
    Executive Summary Aflibercept Market Size and Share Analysis ReportCAGR ValueData Bridge Market Research analyses that the aflibercept market which was USD 8,343.15 million in 2022, and would rocket up to USD 13,911.94 million by 2030, and is expected to undergo a CAGR of 5.40% during the forecast period. This indicates that the market value. “Hospitals” dominates the end user...
    0 Yorumlar 0 hisse senetleri 5 Views 0 önizleme
    Please log in to like, share and comment!
  • EthanWalker bir ses eklendi Other
    2026-10-23 22:16:07 - Translate -
    Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in Europe
    Alvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...
    0 Yorumlar 0 hisse senetleri 2K Views 0 önizleme
    Please log in to like, share and comment!
© 2026 Net Pals Turkish
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
About Koşullar Gizlilik Cookies Acceptable Use Contact Us Rehber